In patients receiving platinum-based chemotherapy, the outcomes of NSCLC patients with bone metastases is poor, with a median survival of less than a year.[22–24] Our study revealed EGFR-TKIs had prolonged the median survival duration from 6.5 months to 15.4 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.